Results 301 to 310 of about 2,867,692 (324)
Some of the next articles are maybe not open access.
Cardiovascular & Haematological Disorders - Drug Targets, 2008
Nonsteroidal anti-inflammatory drugs (NSAIDs) and Aspirin target cyclooxygenase (cox) enzymes and inhibit the synthesis of prostanoids. These drugs were originally developed to reduce the cardinal signs of inflammation, primarily pain.
N. Bunimov, O. Laneuville
semanticscholar +1 more source
Nonsteroidal anti-inflammatory drugs (NSAIDs) and Aspirin target cyclooxygenase (cox) enzymes and inhibit the synthesis of prostanoids. These drugs were originally developed to reduce the cardinal signs of inflammation, primarily pain.
N. Bunimov, O. Laneuville
semanticscholar +1 more source
New cycloalkylpyrazoles as potential cyclooxygenase inhibitors
Il Farmaco, 1998AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
CARDIA, MARIA CRISTINA +5 more
openaire +5 more sources
Pharmacology and efficacy of cyclooxygenase (COX) inhibitors
The American Journal of Medicine, 1999Discussion of the pharmacology and efficacy of cyclooxygenase (COX) inhibition requires careful attention to the methodology used for making those comparisons. In vitro analysis of COX-2/COX-1 ratios requires consideration of the target tissues being examined, the details of incubation periods, outcome measures, and other parameters.
openaire +3 more sources
The Role of Cyclooxygenase Inhibitors in Cancer Prevention
Current Pharmaceutical Design, 2002Carcinogenesis results from the long-term accumulation of genetic and epigenetic aberrations at the molecular level, which are under constant selection pressure for growth advantage. Recognizing that cancer is the result of this long-term, multi-step process provides opportunities for molecularly targeted cancer prevention.
Ernest T. Hawk +3 more
openaire +3 more sources
The Cyclooxygenase-2 Inhibitors: Safety and Effectiveness
Annals of Pharmacotherapy, 1999OBJECTIVE: To review the development of cyclooxygenase-2 (COX-2) inhibitors and discuss specific agents that are currently under investigation or have been marketed. DATA SOURCES: Primary literature on selective COX inhibitors was identified from a comprehensive MEDLINE, English-literature search from January 1966 through September 1998, with ...
Barbara Storyk Klostermeyer +1 more
openaire +2 more sources
Cardiovascular effects of cyclooxygenase-2 inhibitors
Current Opinion in Internal Medicine, 2008Arthritis and musculoskeletal disorders are highly prevalent and management often involves the use of nonsteroidal antiinflammatory drugs. Cyclooxygenase-2 enzyme inhibitors are newer selective nonsteroidal antiinflammatory drugs that purport to exhibit less gastrointestinal toxicity than traditional nonsteroidal antiinflammatory drugs.
openaire +3 more sources
Cyclooxygenase-2 inhibitors and cardiovascular risk
Current Opinion in Cardiology, 2006Cyclooxygenase-2 inhibitors, or coxibs, designed to provide comparable pain relief to traditional nonsteroidal anti-inflammatory drugs with reduced risk of gastrointestinal complications, have come under substantial recent scrutiny because of an increased likelihood of adverse cardiovascular events associated with their use.Data concerning the ...
openaire +3 more sources
Selective Cyclooxygenase-2 Inhibitors
2004Publisher Summary Cyclooxygenase (prostaglandin G/H synthase) catalyzes the conversion of arachidonic acid (AA) into prostaglandin H2 as the first committed step of prostaglandin biosynthesis. This enzyme is known to be the target of acetyl salicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs).
openaire +2 more sources
Cyclooxygenase-2–specific inhibitors: are they safe?
The American Journal of Medicine, 2001The basic tenet of the cyclooxygenase-2 (COX-2) hypothesis rests on the fact that sparing of inhibition of COX-1 should result in greater safety than if both COX isoforms are inhibited. This increase in safety should be most evident in those organs and tissues in which COX-1 alone has important, necessary physiologic functions (e.g., the stomach and ...
openaire +3 more sources
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs.
Biochimica et Biophysica Acta, 2015P. Patrignani, C. Patrono
semanticscholar +1 more source